{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:13:56Z","timestamp":1770484436615,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00535-012-0714-9","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T05:18:42Z","timestamp":1353993522000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines"],"prefix":"10.1007","volume":"48","author":[{"given":"Kazuaki","family":"Chayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waka","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiiku","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,28]]},"reference":[{"key":"714_CR1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000150360","volume":"37","author":"H Okamoto","year":"1994","unstructured":"Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology. 1994;37:68\u201376.","journal-title":"Intervirology"},{"issue":"Suppl 1","key":"714_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74\u201381.","journal-title":"Liver Int"},{"key":"714_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/jlts.2003.50073","volume":"9","author":"GL Davis","year":"2003","unstructured":"Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331\u20138.","journal-title":"Liver Transpl"},{"key":"714_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-2007-1007259","volume":"15","author":"MJ Alter","year":"1995","unstructured":"Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995;15:5\u201314.","journal-title":"Semin Liver Dis"},{"key":"714_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/hep.1840360704","volume":"36","author":"JH Hoofnagle","year":"2002","unstructured":"Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21\u20139.","journal-title":"Hepatology"},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1002\/hep.1840360706","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35\u201346.","journal-title":"Hepatology"},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1440-1746.2010.06550.x","volume":"26","author":"K Chayama","year":"2011","unstructured":"Chayama K, Hayes CN. Hepatitis C virus: how genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26:83\u201395.","journal-title":"J Gastroenterol Hepatol"},{"key":"714_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1872-034X.2009.00634.x","volume":"40","author":"H Kumada","year":"2010","unstructured":"Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:8\u201313.","journal-title":"Hepatol Res"},{"key":"714_CR10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u201355.","journal-title":"Ann Intern Med"},{"key":"714_CR11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958\u201365.","journal-title":"Lancet"},{"key":"714_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u201382.","journal-title":"N Engl J Med"},{"key":"714_CR13","doi-asserted-by":"publisher","unstructured":"Schmitz S, O\u2019Leary A, Walsh C, Bergin C, Norris S. The relative efficacy of boceprevir and telaprevir in the treatment of HCV Genotype 1. Clin Infect Dis. 2012. doi:10.1093\/cid\/cis880","DOI":"10.1093\/cid\/cis880"},{"key":"714_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","volume":"50","author":"RB Perni","year":"2006","unstructured":"Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006;50:899\u2013909.","journal-title":"Antimicrob Agents Chemother"},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.1082604","volume":"300","author":"E Foy","year":"2003","unstructured":"Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003;300:1145\u20138.","journal-title":"Science"},{"key":"714_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","volume":"131","author":"HW Reesink","year":"2006","unstructured":"Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997\u20131002.","journal-title":"Gastroenterology"},{"key":"714_CR17","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767\u201377.","journal-title":"Gastroenterology"},{"key":"714_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24460","volume":"54","author":"N Hiraga","year":"2011","unstructured":"Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology. 2011;54:781\u20138.","journal-title":"Hepatology"},{"key":"714_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s00535-011-0411-0","volume":"46","author":"I Ozeki","year":"2011","unstructured":"Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol. 2011;46:929\u201337.","journal-title":"J Gastroenterol"},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827\u201338.","journal-title":"N Engl J Med"},{"key":"714_CR21","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C Hezode","year":"2009","unstructured":"Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839\u201350.","journal-title":"N Engl J Med"},{"key":"714_CR22","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292\u2013303.","journal-title":"N Engl J Med"},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405\u201316.","journal-title":"N Engl J Med"},{"key":"714_CR24","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. New Engl J Med. 2011;364:2417\u201328.","journal-title":"New Engl J Med"},{"key":"714_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","volume":"35","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012;35:647\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"714_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/infdis\/jir210","volume":"204","author":"K Chayama","year":"2011","unstructured":"Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84\u201393.","journal-title":"J Infect Dis"},{"key":"714_CR27","doi-asserted-by":"publisher","unstructured":"Liu J, Jadhav PR, Amur S, et al. Response guided telaprevir therapy in prior relapsers?: the role of bridging data from treatment-naive and experienced subjects. Hepatol. 2012. doi:10.1002\/hep.25764","DOI":"10.1002\/hep.25764"},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78\u201384.","journal-title":"J Hepatol"},{"key":"714_CR29","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1872-034X.2010.00726.x","volume":"40","author":"K Chayama","year":"2010","unstructured":"Chayama K, Hayes CN, Yoshioka K, et al. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C. Hepatol Res. 2010;40:1155\u201367.","journal-title":"Hepatol Res"},{"key":"714_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000087257","volume":"49","author":"H Yoshizawa","year":"2006","unstructured":"Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology. 2006;49:7\u201317.","journal-title":"Intervirology"},{"key":"714_CR31","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","volume":"19","author":"N Hayashi","year":"2012","unstructured":"Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134\u201342.","journal-title":"J Viral Hepat"},{"key":"714_CR32","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/j.1365-2893.2011.01514.x","volume":"19","author":"I Yamada","year":"2012","unstructured":"Yamada I, Suzuki F, Kamiya N, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12\u00a0weeks in hepatitis C virus genotype 1b infection. J Viral Hepat. 2012;19:e112\u20139.","journal-title":"J Viral Hepat"},{"key":"714_CR33","doi-asserted-by":"crossref","unstructured":"Toyota J, Ozeki I, Karino Y, et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat. 2012.","DOI":"10.1111\/j.1365-2893.2012.01640.x"},{"key":"714_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s10620-008-0500-y","volume":"54","author":"H Sezaki","year":"2009","unstructured":"Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317\u201324.","journal-title":"Dig Dis Sci"},{"key":"714_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192\u2013206.","journal-title":"J Hepatol"},{"key":"714_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46:631\u20139.","journal-title":"Hepatology"},{"key":"714_CR37","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/hep.22549","volume":"48","author":"T Kuntzen","year":"2008","unstructured":"Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769\u201378.","journal-title":"Hepatology"},{"key":"714_CR38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","volume":"130","author":"JL Dienstag","year":"2006","unstructured":"Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231\u201364 (quiz 214\u20137).","journal-title":"Gastroenterology."},{"key":"714_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jhep.2006.09.019","volume":"46","author":"N Akuta","year":"2007","unstructured":"Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46:403\u201310.","journal-title":"J Hepatol"},{"key":"714_CR40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","volume":"128","author":"M Romero-G\u00f3mez","year":"2005","unstructured":"Romero-G\u00f3mez M, Del Mar Viloria M, Andrade R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636\u201341.","journal-title":"Gastroenterology"},{"key":"714_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/hep.510240505","volume":"24","author":"S Zeuzem","year":"1996","unstructured":"Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology. 1996;24:1003\u20139.","journal-title":"Hepatology"},{"key":"714_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"DL Ge","year":"2009","unstructured":"Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399\u2013401.","journal-title":"Nature"},{"key":"714_CR43","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41:1100\u20134.","journal-title":"Nat Genet"},{"key":"714_CR44","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798\u2013801.","journal-title":"Nature"},{"key":"714_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000086064","volume":"48","author":"N Akuta","year":"2005","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372\u201380.","journal-title":"Intervirology"},{"key":"714_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI118025","volume":"96","author":"N Enomoto","year":"1995","unstructured":"Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b\u2014sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. J Clin Invest. 1995;96:224\u201330.","journal-title":"J Clin Invest"},{"key":"714_CR47","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jmv.23262","volume":"84","author":"N Akuta","year":"2012","unstructured":"Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097\u2013105.","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"714_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1478-3231.2011.02709.x","volume":"32","author":"PY Kwo","year":"2012","unstructured":"Kwo PY. Phase III results in genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int. 2012;32(Suppl 1):39\u201343.","journal-title":"Liver Int"},{"key":"714_CR49","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nbt.2020","volume":"29","author":"AD Kwong","year":"2011","unstructured":"Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011;29:993\u20131003.","journal-title":"Nat Biotechnol"},{"key":"714_CR50","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jhep.2010.08.033","volume":"54","author":"E Ohara","year":"2011","unstructured":"Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol. 2011;54:872\u20138.","journal-title":"J Hepatol"},{"key":"714_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216\u201324.","journal-title":"N Engl J Med"},{"key":"714_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742\u20138.","journal-title":"Hepatology"},{"key":"714_CR53","doi-asserted-by":"crossref","unstructured":"Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible\/intolerant to peginterferon. In: 47th annual meeting of the European Association for the study of the liver (EASL 2012). Barcelona, 2012; Abstract 14.","DOI":"10.1016\/S0168-8278(12)60028-2"},{"key":"714_CR54","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep.24744","volume":"55","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2012;55:749\u201358.","journal-title":"Hepatology"},{"key":"714_CR55","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-24.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-012-0714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-012-0714-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00535-012-0714-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-012-0714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:37:35Z","timestamp":1630528655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-012-0714-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,28]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1007\/s00535-012-0714-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,28]]},"assertion":[{"value":"4 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}